1
|
Perricos A, Proestling K, Husslein H, Kuessel L, Hudson QJ, Wenzl R, Yotova I. Hsa-mir-135a Shows Potential as A Putative Diagnostic Biomarker in Saliva and Plasma for Endometriosis. Biomolecules 2022; 12:biom12081144. [PMID: 36009038 PMCID: PMC9405570 DOI: 10.3390/biom12081144] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 08/16/2022] [Accepted: 08/17/2022] [Indexed: 11/16/2022] Open
Abstract
Endometriosis is a chronic disease characterized by the implantation and proliferation of endometrial tissue outside of the uterine cavity. The nonspecific nature of the symptoms and the lack of sensitive, noninvasive diagnostic methods often lead to a significant delay in diagnosis, highlighting the need for diagnostic biomarkers. The correlation of circulating miRNAs with altered inflammatory signals seen in patients with endometriosis has raised the possibility that miRNAs can serve as biomarkers for the disease. In our study, we analyzed miRNA expression in saliva of women with and without endometriosis using a FireFly custom multiplex circulating miRNA assay. This focused panel included 28 human miRNAs, 25 of which have been previously found to be differentially expressed either in plasma, serum, and/or blood of women with endometriosis, compared to controls. We found that hsa-mir-135a was expressed significantly higher in the saliva of women with endometriosis, independent of disease stage and menstrual cycle phase. We confirmed that hsa-mir-135a also showed significantly elevated expression in the plasma of endometriosis patients. This indicates that hsa-mir-135a is a putative noninvasive biomarker of endometriosis in both saliva and plasma, but further validation studies are required to assess its clinical value as a biomarker.
Collapse
|
2
|
Manjunath HS, Kalikiri MKR, Kabeer BSA, Tomei S. When Mosquito HV bites Biomark HD: An automated workflow for high-throughput qPCR. SLAS Technol 2022; 27:219-223. [DOI: 10.1016/j.slast.2021.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
3
|
Goldoni R, Scolaro A, Boccalari E, Dolci C, Scarano A, Inchingolo F, Ravazzani P, Muti P, Tartaglia G. Malignancies and Biosensors: A Focus on Oral Cancer Detection through Salivary Biomarkers. BIOSENSORS-BASEL 2021; 11:bios11100396. [PMID: 34677352 PMCID: PMC8533918 DOI: 10.3390/bios11100396] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 10/11/2021] [Accepted: 10/14/2021] [Indexed: 12/15/2022]
Abstract
Oral cancer is among the deadliest types of malignancy due to the late stage at which it is usually diagnosed, leaving the patient with an average five-year survival rate of less than 50%. The booming field of biosensing and point of care diagnostics can, in this regard, play a major role in the early detection of oral cancer. Saliva is gaining interest as an alternative biofluid for non-invasive diagnostics, and many salivary biomarkers of oral cancer have been proposed. While these findings are promising for the application of salivaomics tools in routine practice, studies on larger cohorts are still needed for clinical validation. This review aims to summarize the most recent development in the field of biosensing related to the detection of salivary biomarkers commonly associated with oral cancer. An introduction to oral cancer diagnosis, prognosis and treatment is given to define the clinical problem clearly, then saliva as an alternative biofluid is presented, along with its advantages, disadvantages, and collection procedures. Finally, a brief paragraph on the most promising salivary biomarkers introduces the sensing technologies commonly exploited to detect oral cancer markers in saliva. Hence this review provides a comprehensive overview of both the clinical and technological advantages and challenges associated with oral cancer detection through salivary biomarkers.
Collapse
Affiliation(s)
- Riccardo Goldoni
- Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, 20122 Milano, Italy; (R.G.); (A.S.); (E.B.); (C.D.); (P.M.)
| | - Alessandra Scolaro
- Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, 20122 Milano, Italy; (R.G.); (A.S.); (E.B.); (C.D.); (P.M.)
| | - Elisa Boccalari
- Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, 20122 Milano, Italy; (R.G.); (A.S.); (E.B.); (C.D.); (P.M.)
| | - Carolina Dolci
- Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, 20122 Milano, Italy; (R.G.); (A.S.); (E.B.); (C.D.); (P.M.)
| | - Antonio Scarano
- Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy;
| | - Francesco Inchingolo
- Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy;
| | - Paolo Ravazzani
- National Research Council, Institute of Electronics, Computer and Telecommunication Engineering (CNR IEIIT), 20133 Milano, Italy;
| | - Paola Muti
- Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, 20122 Milano, Italy; (R.G.); (A.S.); (E.B.); (C.D.); (P.M.)
| | - Gianluca Tartaglia
- Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, 20122 Milano, Italy; (R.G.); (A.S.); (E.B.); (C.D.); (P.M.)
- UOC Maxillo-Facial Surgery and Dentistry, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, 20100 Milano, Italy
- Correspondence:
| |
Collapse
|